Family history of liver cancer may modify the association between HBV infection and liver cancer in a Chinese population
Background & Aims The potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined. Methods We conducted a population‐based case‐control study composed of 2011 liver cancer cases and 7933 controls in Jiangsu province, China from 2003...
Saved in:
| Published in | Liver international Vol. 39; no. 8; pp. 1490 - 1503 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.08.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background & Aims
The potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined.
Methods
We conducted a population‐based case‐control study composed of 2011 liver cancer cases and 7933 controls in Jiangsu province, China from 2003 to 2010. Data on major risk or protective factors were collected and HBV/HCV sero‐markers were assayed using blood samples. Semi‐Bayes (SB) adjustments were applied to provide posterior estimates.
Results
Both family history of liver cancer (adjusted odds ratios [OR]: 4.32, 95% confidence intervals [CI]: 3.25‐5.73) and hepatitis B surface antigen (HBsAg) positivity (adjusted OR: 9.94, 95% CI: 8.33‐11.87) were strongly associated with liver cancer development. For individuals with different combinations of serological markers, the adjusted ORs were 8.45 (95% CI: 5.16‐13.82) for HBsAg‐ and HBcAb‐positive; 7.57 (95% CI: 4.87‐11.77) for HBsAg‐, HBeAg‐ and HBcAb‐positive; and 3.62 (95% CI: 2.47‐5.31) for HBsAg‐, HBeAb‐ and HBcAb‐positive, compared to all negatives in HBV serological markers. One log increase in HBV DNA level was associated with 17% increased risk (adjusted OR: 1.17, 95% CI: 1.03‐1.32). The SB‐adjusted OR of HBV‐positive individuals with family history of liver cancer was 41.34 (95% posterior interval [PI]: 23.69‐72.12) compared with those HBV‐negative without family history. Relative excess risk due to additive interaction, the attributable proportion and synergy index were 73.13, 0.87 and 8.04 respectively. Adjusted ratio of OR for multiplicative interaction was 2.84 (95% CI: 1.41‐5.75).
Conclusions
Super‐additive and super‐multiplicative interactions may exist between family history of liver cancer and HBV infection on the development of liver cancer. |
|---|---|
| AbstractList | Background & AimsThe potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined.MethodsWe conducted a population‐based case‐control study composed of 2011 liver cancer cases and 7933 controls in Jiangsu province, China from 2003 to 2010. Data on major risk or protective factors were collected and HBV/HCV sero‐markers were assayed using blood samples. Semi‐Bayes (SB) adjustments were applied to provide posterior estimates.ResultsBoth family history of liver cancer (adjusted odds ratios [OR]: 4.32, 95% confidence intervals [CI]: 3.25‐5.73) and hepatitis B surface antigen (HBsAg) positivity (adjusted OR: 9.94, 95% CI: 8.33‐11.87) were strongly associated with liver cancer development. For individuals with different combinations of serological markers, the adjusted ORs were 8.45 (95% CI: 5.16‐13.82) for HBsAg‐ and HBcAb‐positive; 7.57 (95% CI: 4.87‐11.77) for HBsAg‐, HBeAg‐ and HBcAb‐positive; and 3.62 (95% CI: 2.47‐5.31) for HBsAg‐, HBeAb‐ and HBcAb‐positive, compared to all negatives in HBV serological markers. One log increase in HBV DNA level was associated with 17% increased risk (adjusted OR: 1.17, 95% CI: 1.03‐1.32). The SB‐adjusted OR of HBV‐positive individuals with family history of liver cancer was 41.34 (95% posterior interval [PI]: 23.69‐72.12) compared with those HBV‐negative without family history. Relative excess risk due to additive interaction, the attributable proportion and synergy index were 73.13, 0.87 and 8.04 respectively. Adjusted ratio of OR for multiplicative interaction was 2.84 (95% CI: 1.41‐5.75).ConclusionsSuper‐additive and super‐multiplicative interactions may exist between family history of liver cancer and HBV infection on the development of liver cancer. Background & Aims The potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined. Methods We conducted a population‐based case‐control study composed of 2011 liver cancer cases and 7933 controls in Jiangsu province, China from 2003 to 2010. Data on major risk or protective factors were collected and HBV/HCV sero‐markers were assayed using blood samples. Semi‐Bayes (SB) adjustments were applied to provide posterior estimates. Results Both family history of liver cancer (adjusted odds ratios [OR]: 4.32, 95% confidence intervals [CI]: 3.25‐5.73) and hepatitis B surface antigen (HBsAg) positivity (adjusted OR: 9.94, 95% CI: 8.33‐11.87) were strongly associated with liver cancer development. For individuals with different combinations of serological markers, the adjusted ORs were 8.45 (95% CI: 5.16‐13.82) for HBsAg‐ and HBcAb‐positive; 7.57 (95% CI: 4.87‐11.77) for HBsAg‐, HBeAg‐ and HBcAb‐positive; and 3.62 (95% CI: 2.47‐5.31) for HBsAg‐, HBeAb‐ and HBcAb‐positive, compared to all negatives in HBV serological markers. One log increase in HBV DNA level was associated with 17% increased risk (adjusted OR: 1.17, 95% CI: 1.03‐1.32). The SB‐adjusted OR of HBV‐positive individuals with family history of liver cancer was 41.34 (95% posterior interval [PI]: 23.69‐72.12) compared with those HBV‐negative without family history. Relative excess risk due to additive interaction, the attributable proportion and synergy index were 73.13, 0.87 and 8.04 respectively. Adjusted ratio of OR for multiplicative interaction was 2.84 (95% CI: 1.41‐5.75). Conclusions Super‐additive and super‐multiplicative interactions may exist between family history of liver cancer and HBV infection on the development of liver cancer. The potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined.BACKGROUND & AIMSThe potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined.We conducted a population-based case-control study composed of 2011 liver cancer cases and 7933 controls in Jiangsu province, China from 2003 to 2010. Data on major risk or protective factors were collected and HBV/HCV sero-markers were assayed using blood samples. Semi-Bayes (SB) adjustments were applied to provide posterior estimates.METHODSWe conducted a population-based case-control study composed of 2011 liver cancer cases and 7933 controls in Jiangsu province, China from 2003 to 2010. Data on major risk or protective factors were collected and HBV/HCV sero-markers were assayed using blood samples. Semi-Bayes (SB) adjustments were applied to provide posterior estimates.Both family history of liver cancer (adjusted odds ratios [OR]: 4.32, 95% confidence intervals [CI]: 3.25-5.73) and hepatitis B surface antigen (HBsAg) positivity (adjusted OR: 9.94, 95% CI: 8.33-11.87) were strongly associated with liver cancer development. For individuals with different combinations of serological markers, the adjusted ORs were 8.45 (95% CI: 5.16-13.82) for HBsAg- and HBcAb-positive; 7.57 (95% CI: 4.87-11.77) for HBsAg-, HBeAg- and HBcAb-positive; and 3.62 (95% CI: 2.47-5.31) for HBsAg-, HBeAb- and HBcAb-positive, compared to all negatives in HBV serological markers. One log increase in HBV DNA level was associated with 17% increased risk (adjusted OR: 1.17, 95% CI: 1.03-1.32). The SB-adjusted OR of HBV-positive individuals with family history of liver cancer was 41.34 (95% posterior interval [PI]: 23.69-72.12) compared with those HBV-negative without family history. Relative excess risk due to additive interaction, the attributable proportion and synergy index were 73.13, 0.87 and 8.04 respectively. Adjusted ratio of OR for multiplicative interaction was 2.84 (95% CI: 1.41-5.75).RESULTSBoth family history of liver cancer (adjusted odds ratios [OR]: 4.32, 95% confidence intervals [CI]: 3.25-5.73) and hepatitis B surface antigen (HBsAg) positivity (adjusted OR: 9.94, 95% CI: 8.33-11.87) were strongly associated with liver cancer development. For individuals with different combinations of serological markers, the adjusted ORs were 8.45 (95% CI: 5.16-13.82) for HBsAg- and HBcAb-positive; 7.57 (95% CI: 4.87-11.77) for HBsAg-, HBeAg- and HBcAb-positive; and 3.62 (95% CI: 2.47-5.31) for HBsAg-, HBeAb- and HBcAb-positive, compared to all negatives in HBV serological markers. One log increase in HBV DNA level was associated with 17% increased risk (adjusted OR: 1.17, 95% CI: 1.03-1.32). The SB-adjusted OR of HBV-positive individuals with family history of liver cancer was 41.34 (95% posterior interval [PI]: 23.69-72.12) compared with those HBV-negative without family history. Relative excess risk due to additive interaction, the attributable proportion and synergy index were 73.13, 0.87 and 8.04 respectively. Adjusted ratio of OR for multiplicative interaction was 2.84 (95% CI: 1.41-5.75).Super-additive and super-multiplicative interactions may exist between family history of liver cancer and HBV infection on the development of liver cancer.CONCLUSIONSSuper-additive and super-multiplicative interactions may exist between family history of liver cancer and HBV infection on the development of liver cancer. The potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined. We conducted a population-based case-control study composed of 2011 liver cancer cases and 7933 controls in Jiangsu province, China from 2003 to 2010. Data on major risk or protective factors were collected and HBV/HCV sero-markers were assayed using blood samples. Semi-Bayes (SB) adjustments were applied to provide posterior estimates. Both family history of liver cancer (adjusted odds ratios [OR]: 4.32, 95% confidence intervals [CI]: 3.25-5.73) and hepatitis B surface antigen (HBsAg) positivity (adjusted OR: 9.94, 95% CI: 8.33-11.87) were strongly associated with liver cancer development. For individuals with different combinations of serological markers, the adjusted ORs were 8.45 (95% CI: 5.16-13.82) for HBsAg- and HBcAb-positive; 7.57 (95% CI: 4.87-11.77) for HBsAg-, HBeAg- and HBcAb-positive; and 3.62 (95% CI: 2.47-5.31) for HBsAg-, HBeAb- and HBcAb-positive, compared to all negatives in HBV serological markers. One log increase in HBV DNA level was associated with 17% increased risk (adjusted OR: 1.17, 95% CI: 1.03-1.32). The SB-adjusted OR of HBV-positive individuals with family history of liver cancer was 41.34 (95% posterior interval [PI]: 23.69-72.12) compared with those HBV-negative without family history. Relative excess risk due to additive interaction, the attributable proportion and synergy index were 73.13, 0.87 and 8.04 respectively. Adjusted ratio of OR for multiplicative interaction was 2.84 (95% CI: 1.41-5.75). Super-additive and super-multiplicative interactions may exist between family history of liver cancer and HBV infection on the development of liver cancer. |
| Author | Zhao, Jin‐Kou Mu, Lina He, Na Li, Gang Jung, Su Yon Li, Liming Han, Ren‐Qiang Wang, Xu‐Shan Baecker, Aileen Liu, Xing Zhou, Jin‐Yi Gu, Xiaoping Yang, Jie Wang, Pei‐Hua Jin, Zi‐Yi Fu, Alan Sun, Zheng Wu, Ming Liu, Ai‐Min Zhang, Xiao‐Feng Su, Ming Hu, Xu Zhang, Zuo‐Feng |
| AuthorAffiliation | 3 Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China 8 Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California 12 Center for Human Nutrition, David Geffen School of Medicine, UCLA, Los Angeles, California 9 School of Nursing, UCLA, Los Angeles, California 10 Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, New York 2 Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China 4 Dafeng Center for Disease Control and Prevention, Dafeng, Jiangsu, China 7 Tongshan County Center for Disease control and Prevention, Tongshan, Jiangsu, China 11 Department of Epidemiology, School of Public Health, Peking University, Beijing, China 5 Ganyu Center for Disease Control and Prevention, Ganyu, Jiangsu, China 6 Chuzhou County Center for Disease Control and Prevention, Chuzhou, Jiangsu, China 1 Department of Epidemiology, Fie |
| AuthorAffiliation_xml | – name: 3 Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China – name: 12 Center for Human Nutrition, David Geffen School of Medicine, UCLA, Los Angeles, California – name: 9 School of Nursing, UCLA, Los Angeles, California – name: 4 Dafeng Center for Disease Control and Prevention, Dafeng, Jiangsu, China – name: 1 Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California – name: 10 Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, New York – name: 2 Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China – name: 5 Ganyu Center for Disease Control and Prevention, Ganyu, Jiangsu, China – name: 11 Department of Epidemiology, School of Public Health, Peking University, Beijing, China – name: 8 Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California – name: 6 Chuzhou County Center for Disease Control and Prevention, Chuzhou, Jiangsu, China – name: 7 Tongshan County Center for Disease control and Prevention, Tongshan, Jiangsu, China |
| Author_xml | – sequence: 1 givenname: Xing orcidid: 0000-0003-1385-9749 surname: Liu fullname: Liu, Xing organization: Fudan University – sequence: 2 givenname: Aileen surname: Baecker fullname: Baecker, Aileen organization: University of California – sequence: 3 givenname: Ming surname: Wu fullname: Wu, Ming organization: Jiangsu Provincial Center for Disease Control and Prevention – sequence: 4 givenname: Jin‐Yi surname: Zhou fullname: Zhou, Jin‐Yi organization: Jiangsu Provincial Center for Disease Control and Prevention – sequence: 5 givenname: Jie surname: Yang fullname: Yang, Jie organization: Jiangsu Provincial Center for Disease Control and Prevention – sequence: 6 givenname: Ren‐Qiang surname: Han fullname: Han, Ren‐Qiang organization: Jiangsu Provincial Center for Disease Control and Prevention – sequence: 7 givenname: Pei‐Hua surname: Wang fullname: Wang, Pei‐Hua organization: Jiangsu Provincial Center for Disease Control and Prevention – sequence: 8 givenname: Zi‐Yi surname: Jin fullname: Jin, Zi‐Yi organization: Fudan University – sequence: 9 givenname: Ai‐Min surname: Liu fullname: Liu, Ai‐Min organization: Dafeng Center for Disease Control and Prevention – sequence: 10 givenname: Xiaoping surname: Gu fullname: Gu, Xiaoping organization: Dafeng Center for Disease Control and Prevention – sequence: 11 givenname: Xiao‐Feng surname: Zhang fullname: Zhang, Xiao‐Feng organization: Ganyu Center for Disease Control and Prevention – sequence: 12 givenname: Xu‐Shan surname: Wang fullname: Wang, Xu‐Shan organization: Ganyu Center for Disease Control and Prevention – sequence: 13 givenname: Ming surname: Su fullname: Su, Ming organization: Chuzhou County Center for Disease Control and Prevention – sequence: 14 givenname: Xu surname: Hu fullname: Hu, Xu organization: Chuzhou County Center for Disease Control and Prevention – sequence: 15 givenname: Zheng surname: Sun fullname: Sun, Zheng organization: Tongshan County Center for Disease control and Prevention – sequence: 16 givenname: Gang surname: Li fullname: Li, Gang organization: Tongshan County Center for Disease control and Prevention – sequence: 17 givenname: Alan surname: Fu fullname: Fu, Alan organization: University of California – sequence: 18 givenname: Su Yon surname: Jung fullname: Jung, Su Yon organization: UCLA – sequence: 19 givenname: Lina surname: Mu fullname: Mu, Lina organization: University at Buffalo, The State University of New York – sequence: 20 givenname: Na surname: He fullname: He, Na organization: Fudan University – sequence: 21 givenname: Liming surname: Li fullname: Li, Liming organization: Peking University – sequence: 22 givenname: Jin‐Kou surname: Zhao fullname: Zhao, Jin‐Kou organization: Jiangsu Provincial Center for Disease Control and Prevention – sequence: 23 givenname: Zuo‐Feng surname: Zhang fullname: Zhang, Zuo‐Feng email: zfzhang@ucla.edu organization: David Geffen School of Medicine, UCLA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31228882$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kcFu1DAQhi1URNuFAy-ALHGBw7axHcf2BamsKK20Ehfo1XKcMevKsZc4acnbY3bLilYCX8aa-ebXPzOn6CimCAi9JtUZKe88-LszUhNJn6ETUgu5ZJSRo8OfsmN0mvNtVRGlOHmBjhmhVEpJT9DPS9P7MOONz2MaZpwcLmowYGuiLaE3M-5T592Mxw1gk3Oy3ow-RdzCeA8Q8dXHG-yjA7vLmtg9VvAlh1cbHyED3qbtFHbtL9FzZ0KGVw9xgb5dfvq6ulquv3y-Xl2sl7auGV1aULyRYI1SqrWsES11xhLoalIJw2vnQALhnNi2Uw2XkikiuHKMO0d5a9gCfdjrbqe2h85CHAcT9HbwvRlmnYzXjyvRb_T3dKcbUXFCRRF49yAwpB8T5FH3PlsIwURIU9aU1ryhoip2F-jtE_Q2TUMs4xWqEVQI2shCvfnb0cHKn6MU4P0esEPKeQB3QEilfx9clwXr3cELe_6EtX7cLbgM48P_Ou59gPnf0np9fbPv-AWyjL3s |
| CitedBy_id | crossref_primary_10_1016_j_jep_2023_117125 crossref_primary_10_1038_s41575_022_00726_3 crossref_primary_10_2139_ssrn_4089047 crossref_primary_10_1016_j_talanta_2021_122675 crossref_primary_10_1016_j_snb_2020_127829 crossref_primary_10_1016_j_clinre_2021_101758 crossref_primary_10_1186_s40001_024_01942_0 crossref_primary_10_1016_j_biopha_2021_111612 crossref_primary_10_1007_s11912_024_01605_7 crossref_primary_10_1186_s12951_025_03214_3 crossref_primary_10_1038_s41598_024_53812_8 crossref_primary_10_3748_wjg_v27_i37_6262 crossref_primary_10_1109_ACCESS_2022_3215706 crossref_primary_10_1002_iid3_1134 crossref_primary_10_3748_wjg_v27_i17_2025 crossref_primary_10_1016_j_jconrel_2021_03_030 |
| Cites_doi | 10.1159/000264201 10.1111/j.1440-1746.2004.03360.x 10.1097/CEJ.0000000000000262 10.1093/carcin/bgm252 10.1111/j.1440-1746.1995.tb01370.x 10.1016/j.jhep.2004.10.005 10.1002/hep.24794 10.1111/j.1440-1746.2011.06695.x 10.1002/ijc.28792 10.3748/wjg.v22.i41.9069 10.3748/wjg.v11.i28.4431 10.1046/j.1440-1746.2001.02616.x 10.1016/S0140-6736(98)09148-X 10.1002/cncr.20427 10.18632/oncotarget.10335 10.1007/s10654-005-7835-x 10.3322/caac.21492 10.1016/j.vaccine.2009.08.048 10.3109/00365520903450113 10.1111/j.1478-3231.2005.01077.x 10.1200/JCO.2007.13.2043 10.1093/ije/dyl289 10.1093/jnci/dji043 10.7314/APJCP.2013.14.12.7251 10.1016/j.canlet.2008.10.040 10.1002/ijc.31181 10.1001/jama.295.1.65 10.1016/j.cancergen.2017.06.002 10.1097/CEJ.0000000000000428 |
| ContentType | Journal Article |
| Copyright | 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. 2019 John Wiley & Sons A/S |
| Copyright_xml | – notice: 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd – notice: 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. – notice: 2019 John Wiley & Sons A/S |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7T5 7U9 8FD FR3 H94 K9. P64 RC3 7X8 5PM |
| DOI | 10.1111/liv.14182 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | Genetics Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1478-3231 |
| EndPage | 1503 |
| ExternalDocumentID | PMC6705127 31228882 10_1111_liv_14182 LIV14182 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: T32 CA009142 – fundername: NINR NIH HHS grantid: K01 NR017852 – fundername: NHLBI NIH HHS grantid: U01 HL146333 – fundername: NIAID NIH HHS grantid: U01 AI035040 – fundername: FIC NIH HHS grantid: D43 TW000013 – fundername: NIEHS NIH HHS grantid: R21 ES011667 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 29L 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 1OB 7QO 7T5 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY FR3 H94 K9. P64 RC3 7X8 5PM |
| ID | FETCH-LOGICAL-c4432-ce9568eca999bc367b2fac1ed4107a54ffe8e1551cbd96588391759f35ff25ba3 |
| IEDL.DBID | DR2 |
| ISSN | 1478-3223 1478-3231 |
| IngestDate | Thu Aug 21 14:32:04 EDT 2025 Thu Jul 10 22:02:48 EDT 2025 Wed Aug 13 08:30:30 EDT 2025 Thu Apr 03 07:00:57 EDT 2025 Tue Jul 01 04:10:05 EDT 2025 Thu Apr 24 23:07:04 EDT 2025 Wed Jan 22 16:39:49 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | interaction hepatitis B Virus serological marker family history hepatocellular carcinoma |
| Language | English |
| License | 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4432-ce9568eca999bc367b2fac1ed4107a54ffe8e1551cbd96588391759f35ff25ba3 |
| Notes | Funding information This project was partially supported by the Jiangsu Provincial Health Department (RC 2003090, PI: Dr Zhao); the NIH National Institute of Environmental Health Sciences, National Cancer Institute, Department of Health and Human Services, Grants ES06718, ES011667, T32 CA09142, NIH/Fogarty D43 TW000013‐21S2, D43 TW000013‐20S, as well as the Alper Research Program of Environmental Genomics of the UCLA Jonsson Comprehensive Cancer Center. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Jin-Kou Zhao and Zuo-Feng Zhang are co-senior authors. |
| ORCID | 0000-0003-1385-9749 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/6705127 |
| PMID | 31228882 |
| PQID | 2267277268 |
| PQPubID | 2045125 |
| PageCount | 14 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6705127 proquest_miscellaneous_2245627044 proquest_journals_2267277268 pubmed_primary_31228882 crossref_primary_10_1111_liv_14182 crossref_citationtrail_10_1111_liv_14182 wiley_primary_10_1111_liv_14182_LIV14182 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | August 2019 |
| PublicationDateYYYYMMDD | 2019-08-01 |
| PublicationDate_xml | – month: 08 year: 2019 text: August 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Liver international |
| PublicationTitleAlternate | Liver Int |
| PublicationYear | 2019 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2018; 142 2004; 101 2010; 31 2010; 53 2012 2017; 26 1995; 10 2006; 295 2005; 42 2005; 20 2011; 32 2004 2012; 55 2009; 27 2007; 36 2018; 68 2014; 135 2005; 25 2010; 45 2012; 92 2016; 7 2013; 14 2013; 11 2004; 19 2008; 29 2009; 286 2008; 26 2017; 216–217 2018 2005; 97 2001; 16 1999; 353 2011; 26 2005; 11 2010; 96 2012; 21 2009; 17 2016; 22 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 Chen Q (e_1_2_9_27_1) 2009; 17 Chen Y (e_1_2_9_7_1) 2011; 32 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_18_1 Chen J (e_1_2_9_25_1) 2010; 31 e_1_2_9_20_1 e_1_2_9_22_1 Loomba R (e_1_2_9_19_1) 2013; 11 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 Zhou J (e_1_2_9_21_1) 2012; 21 e_1_2_9_26_1 e_1_2_9_28_1 e_1_2_9_29_1 Sun Y (e_1_2_9_37_1) 2012; 92 |
| References_xml | – volume: 19 start-page: 670 year: 2004 end-page: 675 article-title: High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection publication-title: J Gastroenterol Hepatol – volume: 101 start-page: 1009 year: 2004 end-page: 1017 article-title: Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. publication-title: Cancer – volume: 53 start-page: 111 year: 2010 end-page: 118 article-title: Impact of serial hepatitis B virus DNA on hepatocellular carcinoma development in patients with liver cirrhosis publication-title: Intervirology – volume: 26 start-page: 628 year: 2011 end-page: 638 article-title: Natural history of chronic hepatitis B REVEALed publication-title: J Gastroenterol Hepatol – volume: 216–217 start-page: 37 year: 2017 end-page: 51 article-title: Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets publication-title: Cancer Genet – volume: 26 start-page: 177 year: 2008 end-page: 182 article-title: High viral load and hepatitis B virus subgenotype are associated with increased risk of hepatocellular carcinoma publication-title: J Clin Oncol Off J Am Soc Clin Oncol – volume: 36 start-page: 195 year: 2007 end-page: 202 article-title: Bayesian perspectives for epidemiological research. II. regression analysis publication-title: Int J Epidemiol – volume: 21 start-page: 570 year: 2012 end-page: 573 article-title: The mortality trend of malignancies in Jiangsu province, 1973–2010 publication-title: China Cancer – volume: 7 start-page: 49299 year: 2016 end-page: 49309 article-title: The contribution of serum hepatitis B virus load in the carcinogenesis and prognosis of hepatocellular carcinoma: evidence from two meta‐analyses publication-title: Oncotarget – volume: 92 start-page: 1874 year: 2012 end-page: 1877 article-title: Relationship between serum hepatitis B virus DNA load and hepatocellular carcinoma in Qidong, China: a cohort follow‐up study of 14 years (in Chinese) publication-title: Natl Med J China – volume: 31 start-page: 721 year: 2010 end-page: 726 article-title: A thirty‐one year prospective follow‐up program on the HBsAg carrier state and primary liver cancer in Qidong, China (in Chinese) publication-title: Chin J Epidemiol – volume: 96 year: 2010 – year: 2012 – volume: 32 start-page: 888 year: 2011 end-page: 891 article-title: A sero‐epidemiological study on hepatitis C in China (in Chinese) publication-title: Chin J Epidemiol – volume: 22 start-page: 9069 year: 2016 end-page: 9095 article-title: Genetic alterations in hepatocellular carcinoma: an update publication-title: World J Gastroenterol – volume: 29 start-page: 106 year: 2008 end-page: 112 article-title: Long‐term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men publication-title: Carcinogenesis – volume: 68 start-page: 394 issue: 6 year: 2018 end-page: 424 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA: Cancer J Clin – volume: 353 start-page: 1253 year: 1999 end-page: 1257 article-title: Hepatocellular carcinoma publication-title: Lancet – volume: 11 start-page: e3 issue: 1636–1645 year: 2013 article-title: Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma publication-title: Clin Gastroenterol Hepatol – volume: 45 start-page: 243 year: 2010 end-page: 249 article-title: Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection publication-title: Scand J Gastroenterol – volume: 20 start-page: 575 year: 2005 end-page: 579 article-title: Calculating measures of biological interaction publication-title: Eur J Epidemiol – volume: 25 start-page: 220 year: 2005 end-page: 225 article-title: Influence of viral load and genotype in the progression of Hepatitis B‐associated liver cirrhosis to hepatocellular carcinoma publication-title: Liver Int Off J Int Assoc Study Liver – volume: 142 start-page: 1560 year: 2018 end-page: 1567 article-title: Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver cancer in a Chinese population publication-title: Int J Cancer – volume: 286 start-page: 9 year: 2009 end-page: 14 article-title: Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection publication-title: Cancer Lett – volume: 27 start-page: 6550 year: 2009 end-page: 6557 article-title: Epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to Hepatitis B vaccination publication-title: Vaccine – year: 2004 – volume: 10 start-page: 674 year: 1995 end-page: 682 article-title: Primary prevention of hepatocellular carcinoma publication-title: J Gastroenterol Hepatol – volume: 295 start-page: 65 year: 2006 end-page: 73 article-title: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level publication-title: JAMA – volume: 16 start-page: 1274 year: 2001 end-page: 1281 article-title: High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis publication-title: J Gastroenterol Hepatol – volume: 14 start-page: 7251 year: 2013 end-page: 7256 article-title: Attributable causes of liver cancer mortality and incidence in China publication-title: Asian Pac J Cancer Prev – volume: 17 start-page: 930 year: 2009 end-page: 934 article-title: A prospective study of the relationship between serum hepatitis B virus DNA and the risk of primary liver cancer (in Chinese) publication-title: Chin J Hepatol – volume: 135 start-page: 1605 year: 2014 end-page: 1614 article-title: Prospective cohort studies of association between family history of liver cancer and risk of liver cancer publication-title: Int J Cancer – volume: 55 start-page: 1416 year: 2012 end-page: 1425 article-title: Family history of liver cancer and hepatocellular carcinoma publication-title: Hepatology – volume: 42 start-page: 218 year: 2005 end-page: 224 article-title: Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma publication-title: J Hepatol – year: 2018 article-title: Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors publication-title: Eur J Cancer Prev – volume: 11 start-page: 4431 year: 2005 end-page: 4434 article-title: Risk factors for primary liver carcinoma in Chinese population publication-title: World J Gastroenterol – volume: 26 start-page: 357 issue: 4 year: 2017 end-page: 364 article-title: Jiangsu four cancers study: a large case‐control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China publication-title: Eur J Cancer Prev – volume: 97 start-page: 265 year: 2005 end-page: 272 article-title: Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men publication-title: J Natl Cancer Inst – ident: e_1_2_9_30_1 doi: 10.1159/000264201 – ident: e_1_2_9_32_1 doi: 10.1111/j.1440-1746.2004.03360.x – ident: e_1_2_9_22_1 doi: 10.1097/CEJ.0000000000000262 – ident: e_1_2_9_33_1 doi: 10.1093/carcin/bgm252 – ident: e_1_2_9_15_1 doi: 10.1111/j.1440-1746.1995.tb01370.x – ident: e_1_2_9_18_1 doi: 10.1016/j.jhep.2004.10.005 – ident: e_1_2_9_10_1 doi: 10.1002/hep.24794 – ident: e_1_2_9_36_1 doi: 10.1111/j.1440-1746.2011.06695.x – volume: 11 start-page: e3 issue: 1636 year: 2013 ident: e_1_2_9_19_1 article-title: Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma publication-title: Clin Gastroenterol Hepatol – ident: e_1_2_9_11_1 doi: 10.1002/ijc.28792 – ident: e_1_2_9_38_1 doi: 10.3748/wjg.v22.i41.9069 – ident: e_1_2_9_9_1 doi: 10.3748/wjg.v11.i28.4431 – ident: e_1_2_9_28_1 doi: 10.1046/j.1440-1746.2001.02616.x – ident: e_1_2_9_3_1 doi: 10.1016/S0140-6736(98)09148-X – ident: e_1_2_9_17_1 doi: 10.1002/cncr.20427 – volume: 31 start-page: 721 year: 2010 ident: e_1_2_9_25_1 article-title: A thirty‐one year prospective follow‐up program on the HBsAg carrier state and primary liver cancer in Qidong, China (in Chinese) publication-title: Chin J Epidemiol – ident: e_1_2_9_35_1 doi: 10.18632/oncotarget.10335 – volume: 21 start-page: 570 year: 2012 ident: e_1_2_9_21_1 article-title: The mortality trend of malignancies in Jiangsu province, 1973–2010 publication-title: China Cancer – ident: e_1_2_9_24_1 doi: 10.1007/s10654-005-7835-x – ident: e_1_2_9_2_1 doi: 10.3322/caac.21492 – ident: e_1_2_9_6_1 doi: 10.1016/j.vaccine.2009.08.048 – ident: e_1_2_9_13_1 – volume: 17 start-page: 930 year: 2009 ident: e_1_2_9_27_1 article-title: A prospective study of the relationship between serum hepatitis B virus DNA and the risk of primary liver cancer (in Chinese) publication-title: Chin J Hepatol – ident: e_1_2_9_29_1 doi: 10.3109/00365520903450113 – ident: e_1_2_9_31_1 doi: 10.1111/j.1478-3231.2005.01077.x – volume: 32 start-page: 888 year: 2011 ident: e_1_2_9_7_1 article-title: A sero‐epidemiological study on hepatitis C in China (in Chinese) publication-title: Chin J Epidemiol – ident: e_1_2_9_8_1 – ident: e_1_2_9_26_1 doi: 10.1200/JCO.2007.13.2043 – ident: e_1_2_9_12_1 – ident: e_1_2_9_20_1 doi: 10.1093/ije/dyl289 – ident: e_1_2_9_34_1 doi: 10.1093/jnci/dji043 – ident: e_1_2_9_16_1 doi: 10.7314/APJCP.2013.14.12.7251 – ident: e_1_2_9_4_1 doi: 10.1016/j.canlet.2008.10.040 – ident: e_1_2_9_14_1 doi: 10.1002/ijc.31181 – ident: e_1_2_9_23_1 doi: 10.1001/jama.295.1.65 – volume: 92 start-page: 1874 year: 2012 ident: e_1_2_9_37_1 article-title: Relationship between serum hepatitis B virus DNA load and hepatocellular carcinoma in Qidong, China: a cohort follow‐up study of 14 years (in Chinese) publication-title: Natl Med J China – ident: e_1_2_9_39_1 doi: 10.1016/j.cancergen.2017.06.002 – ident: e_1_2_9_5_1 doi: 10.1097/CEJ.0000000000000428 |
| SSID | ssj0019951 |
| Score | 2.3983436 |
| Snippet | Background & Aims
The potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined.
Methods
We... The potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined. We conducted a population-based... Background & AimsThe potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined.MethodsWe... The potential interaction between family history of liver cancer and HBV infection on liver cancer has not been fully examined.BACKGROUND & AIMSThe potential... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1490 |
| SubjectTerms | Aged Aged, 80 and over Antigens Bayesian analysis Case-Control Studies China - epidemiology Confidence intervals Deoxyribonucleic acid DNA family history Family medical history Female Genetics Health risk assessment Hepatitis Hepatitis B Hepatitis B - complications Hepatitis B e antigen Hepatitis B surface antigen hepatitis B Virus hepatocellular carcinoma Humans Infections interaction Liver Liver cancer Liver Neoplasms - epidemiology Liver Neoplasms - genetics Liver Neoplasms - virology Male Markers Middle Aged Population studies Risk factors serological marker |
| Title | Family history of liver cancer may modify the association between HBV infection and liver cancer in a Chinese population |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.14182 https://www.ncbi.nlm.nih.gov/pubmed/31228882 https://www.proquest.com/docview/2267277268 https://www.proquest.com/docview/2245627044 https://pubmed.ncbi.nlm.nih.gov/PMC6705127 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEB4hDqgXKOHRFIqmCCEuRrDe2I56oogorQoHBIgDkrW73lWjJg4iCSL8-s6sHxCgUsXNssePtWd2v_F--w3AjtHa2MSR82ZWBJLGwEDJLAy0a4dtpSMbGc-2OIu6l_Lndet6Dr5Va2EKfYj6hxtHhu-vOcCVHj0L8n7vnsKc4DH1v8zVYkB0XktH8cpjn2xJnv6nMbBUFWIWT33m7Fj0CmC-5kk-x69-AOoswU316AXv5M_-ZKz3zeMLVcd3tu0jLJbAFI8KT1qGOZs3YOUop6R8MMVd9FRR_w--AQun5Yz8CjwUlTOw0C2e4tBhn6keaNid7nCgpjgYZj03RYKaqJ68AUuKGHa_X2HFCctR5dnsFXq0D7nMtx1ZvK3rja3CZefk4rgblNUcAiNlKAJjeWWiNYogqTZhFGvhlDm0maQMVLWkczaxDOCMzliRhpAbQZu2C1vOiZZW4RrM58PcfgI0BKJcJmyknZFkoGWkeQYpNImOhbJN2Ku-a2pKqXOuuNFPq5SH2pH6F9yE7dr0ttD3eMtos3KOtAzxUUq4lbBfLKKkCV_rwxScPOOicjucsA0nmPGBlE1YL3ypvkt4KESS8MXjGS-rDVj4e_ZI3vvtBcCjmLpSEVMzvRP9-8HTXz-u_Mbn_zfdgA8ECtsFyXET5sd3E_uFgNdYb_kI-wsRfi03 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VIgGXAi2PbQsMCBCXVNTxJtkDh0KptvRxQG3VW2o7tlixm1TdXWj4TfwV_hMzzoMuBYlLD9w2m5GTODOez_HnbwCeG62NTRw5b2ZFICkHBkpmYaBdL-wpHdnIeLbFftQ_lB-Ou8dz8L3ZC1PpQ7Qf3Dgy_HjNAc4fpC9E-XDwheKc8HFNqdyx5VeasI3fbG_S230hxNb7g3f9oK4pEBgpQxEYy_vjrFEEjLQJo1gLp8y6zSTNg1RXOmcTyzDC6Ix1UQg_UILtubDrnOhqFVK71-A6VxBnpf7Nj61YFe919tM7yYQDyrq1jhHzhtpbnc1-lyDtZWbmRcTsU97WbfjRdFbFdPm8Np3oNfPtNx3J_6U378BCjb1xowqWuzBn80VY2sjVpBiV-BI9G9YvMyzCjb2adLAE51VxEKykmUssHA6ZzYKGI-YMR6rEUZENXImEplH9cnisWXDYf3uEDe0tR5Vnsy0M6D_kSuZ2bPG0Lal2Dw6vpDvuw3xe5PYhoCGc6DJhI-2MJAMtI82LZKFJdCyU7cCrxpFSU6u5c1GRYdrM6ug5Uv9CO_CsNT2tJEz-ZLTaeGNaj2LjlKA5wdtYREkHnranafzhRSWV22LKNjyHjl9L2YEHlfO2VwnXhUgSbjyecevWgLXNZ8_kg09e4zyKKVuImB7Te-3fbzzd3T7yP5b_3fQJ3Owf7O3S8f7OCtwiDNyrOJ2rMD85m9pHhDMn-rEPb4STq46An7KRi_Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VIlVceLQ8AgUGBIiLq3a98ePAoRCilEKFEK16M7vrXRGROFGTAOYv8Vf4UcysHzQUJC49cIvj0dpez-x86_32G4BHRmtjE0fOm1sRSMqBgZJ5GGiXhqnSkY2MZ1scRIND-eq4e7wC35u9MJU-RPvBjSPDj9cc4NPcnQry0fAzhTnB45pRuW_LLzRfmz3b69HLfSxE_-X7F4OgLikQGClDERjL2-OsUYSLtAmjWAunzI7NJU2DVFc6ZxPLKMLonGVRCD5Qfk1d2HVOdLUKqd0LcFFG2ynXiei9a7WqeKuzn91J5htQ0q1ljJg21N7qcvI7g2jPEjNPA2af8fpX4EfTVxXR5dPWYq63zLffZCT_k868Cpdr5I27VahcgxVbrMPGbqHmk3GJT9BzYf0iwzqsvakpBxvwtSoNgpUwc4kThyPmsqDheDnBsSpxPMmHrkTC0qh-uTvWHDgcPD_ChvRWoCry5RaG9B9yHXM7szhtC6pdh8Nz6Y4bsFpMCnsL0BBKdLmwkXZGkoGWkeYlstAkOhbKduBp40eZqbXcuaTIKGvmdPQcmX-hHXjYmk4rAZM_GW02zpjVY9gsI2BO4DYWUdKBB-1pGn14SUkVdrJgG55Bx9tSduBm5bvtVcIdIZKEG4-XvLo1YGXz5TPF8KNXOI9iyhUipsf0Tvv3G89e7x35H7f_3fQ-rL3t9enwYP8OXCIAnFaEzk1YnZ8s7F0CmXN9zwc3wofzDoCfgNuKow |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Family+history+of+liver+cancer+may+modify+the+association+between+HBV+infection+and+liver+cancer+in+a+Chinese+population&rft.jtitle=Liver+international&rft.au=Liu%2C+Xing&rft.au=Baecker%2C+Aileen&rft.au=Wu%2C+Ming&rft.au=Jin%E2%80%90Yi+Zhou&rft.date=2019-08-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1478-3223&rft.eissn=1478-3231&rft.volume=39&rft.issue=8&rft.spage=1490&rft.epage=1503&rft_id=info:doi/10.1111%2Fliv.14182&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon |